Nevertheless, higher SMARCB1 expression correlated with significant extended PFIs in TKI-treated early-stage patients compared to lower levels, consistent with studies linking mSWI/SNF subunit alterations to reduced progression-free survival in EGFR-TKI therapy for lung cancer [46]. This evidence concerns the gene EGFR and lung cancer.